Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gedeon Richter Sees Profit Jump By 40%

Driven By Strong Vraylar Tailwind As Cariprazine Brand Beats Expectations

Executive Summary

A strong tailwind from antipsychotic drug Vraylar helped Hungary’s Gedeon Richter to post a 40% leap in 2019 net profit. Analysts see more upside ahead for eastern Europe’s largest drugmaker.

You may also be interested in...



Teriparatide Trickles In For Richter

Richter’s Terrosa biosimilar to Lilly’s Forsteo teriparatide brand made a modest start in Europe. But the Hungarian group still posted nine-month Pharmaceutical sales growth of 8.1%.

Alvogen Targets Esmya With First European Rival

Alvogen has gained European approvals for a rival to Gedeon Richter’s Esmya through the decentralized procedure.

Top US Court Lifts Discovery Stay On Price-Fixing

The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.

Topics

Related Companies

UsernamePublicRestriction

Register

GB149634

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel